Bid BH3-R8 - 0.5 mg
- Cat.Number : AS-61715
 - Manufacturer Ref. :
 - 
                                Availability : 
        In stock
 
The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.
Specifications
| Chemistry | |
| Sequence one letter code | 
                                    
  | 
                        
|---|---|
| Sequence three letter code | 
                                    
  | 
                        
| Molecular Formula | 
                                    
  | 
                        
| Molecular Mass/ Weight | 
                                    
  | 
                        
| Modification | |
| Conjugation | 
                                    
  | 
                        
| Quantity & Purity | |
| Purity | 
                                    
  | 
                        
| Storage & stability | |
| Form | 
                                    
  | 
                        
| Storage Conditions | 
                                    
  | 
                        
| Activity | |
| Biomarker Target | |
| Research Area | |
| Sub-category Research Area | |
| Usage | 
                                    
  | 
                        
| Source | |
| Source / Species | 
                                    
  | 
                        
You may also be interested in the following product(s)
            
            
            References
Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets
Arch Immunol Ther Exp (Warsz) . 2005 Jan 31 ; 53(1) 47
- F. Mendoza
 - et al
 
Pharmacological manipulation of Bcl-2 family members to control cell death
J Clin Invest . 2005 Oct 01 ; 115(10) 2648 | DOI : 10.1172/JCI26250
- A. Letai